ERBB2 and neoplasm: Anti‐HER‐2‐coated immunoliposomes were superior in controlling tumor growth in vivo, with tumor volume averages in accordance with 25.27%, 44.38%, and 47.78% of tumor volume of untreated control, free PTX/RAP solution and PTX/RAP coloaded liposomes, respectively.